Table 1.
Patient characteristics
| Total (%) | |
|---|---|
| Age, y | Median: 54 |
| ≤40 | 11 (16) |
| 41-50 | 20 (30) |
| 51-60 | 8 (12) |
| 61-70 | 22 (33) |
| >70 | 6 (9) |
| Laterality | |
| Right | 38 (57) |
| Left | 28 (42) |
| Bilateral | 1 (2) |
| Final Stage* | |
| IIA | 14 (21) |
| IIB | 25 (37) |
| IIIA | 22 (33) |
| IIIB | 4 (6) |
| IIIC | 2 (3) |
| Histology | |
| IDC | 62 (93) |
| ILC | 5 (7) |
| Grade | |
| I | 10 (15) |
| II | 18 (27) |
| III | 38 (57) |
| ECE | |
| No | 35 (52) |
| Yes | 18 (27) |
| Unknown | 14 (21) |
| LVSI | |
| No | 33 (49) |
| Yes | 27 (40) |
| Unknown | 7 (10) |
| ER+ | 51 (76) |
| PR+ | 45 (67) |
| Her2+† | 15 (22) |
| ER–/PR–/Her2– | 9 (13) |
Abbreviations: ECE = extracapsular extension; ER = estrogen receptor; LVSI = lymphovascular space invasion; PR = progesterone receptor.
*
Higher of pathologic or prechemotherapy clinical stage.
†
100% of Her2 patients received Her2-directed therapy.